Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial by Herbst, Roy S, Prof, Baas, Paul, Prof, Kim, Dong-Wan, MD, Felip, Enriqueta, MD, Pérez-Gracia, José L, MD, Han, Ji-Youn, Prof, Molina, Julian, MD, Kim, Joo-Hang, Prof, Arvis, Catherine Dubos, MD, Ahn, Myung-Ju, Prof, Majem, Margarita, MD, Fidler, Mary J, MD, de Castro, Gilberto, MD, Garrido, Marcelo, MD, Lubiniecki, Gregory M, MD, Shentu, Yue, PhD, Im, Ellie, MD, Dolled-Filhart, Marisa, PhD, Garon, Edward B, MD

Get full text

Molecular Imaging of Activated von Willebrand Factor to Detect High-Risk Atherosclerotic Phenotype by McCarty, Owen J.T., PhD, Conley, Robert B., BS, Shentu, Weihui, MD, Tormoen, Garth W., MS, Zha, Daogang, MD, Xie, Aris, BS, Qi, Yue, MD, Zhao, Yan, MD, Carr, Chad, MD, Belcik, Todd, RDCS, Keene, Douglas R., BS, de Groot, Philip G., PhD, Lindner, Jonathan R., MD

Get full text